Zosyn is an antibiotic drug owned by Wyeth Pharmaceuticals. It contains the active ingredients Piperacillin Sodium and Tazobactam Sodium. The drug was first authorized for market use on 22nd October 1993. Zosyn holds a total of 3 patents, all of which have already expired.
Although Zosyn's patents have already expired, the generic versions of Zosyn are scheduled for release after 14th April 2023. This is due to the terms of the Hatch-Waxman Act, which allows companies to apply for sole marketing rights for generic drugs before the expiry of a patent. As such, the generic version of Zosyn will only be commercially available after this date.
Zosyn is mainly used in the treatment of bacterial infections. The combination of Piperacillin Sodium and Tazobactam Sodium in Zosyn makes it effective. Piperacillin Sodium works by inhibiting bacterial cell wall synthesis, leading to cell death. Tazobactam Sodium, on the other hand, enhances the effectiveness of Piperacillin Sodium by inhibiting the production of beta-lactamase, an enzyme produced by bacteria to resist antibiotics. As a result, Zosyn can effectively treat infections caused by beta-lactamase producing bacteria.
Zosyn's last patent named 'Compositions containing piperacillin and tazobactam useful for injection' is due to expire on 14th April 2023. After this date, Zosyn's generic versions will become commercially available. Below are the details of the patent: